news Archive - Page 2 of 47

Braxia Scientific Presents Positive Preliminary Findings from Phase II Randomized, Multi-Dose Clinical Trial of Psilocybin-Assisted Therapy for Treatment Resistant Depression

Braxia Scientific has announced positive preliminary results from the first Health Canada Approved, Phase II, randomized clinical trial to evaluate the feasibility, safety, tolerability, and efficacy of multi-dose psilocybin-assisted therapy for treatment-resistant depression. Preliminary results indicate strong feasibility with adequate recruitment including 159 individuals who were referred to the study and clinically meaningful improvements in …

Launch of the Psychedelic Access and Research European Alliance – PAREA

PAREA is a non-profit, multistakeholder and multidisciplinary partnership bringing together patient organizations, medical associations, scientific societies, psychedelic foundations, and the for-profit sector in an effort to change perceptions about psychedelic-assisted therapies, raise awareness of the scientific advances and, ultimately, bring better health to European citizens.

Cybin Receives Institutional Review Board Approval for its Phase 1/2a Clinical Trial Evaluating CYB003 for the Treatment of Major Depressive Disorder

Cybin has announced that it has received Institutional Review Board approval to begin the first-in-human Phase I/IIa clinical trial evaluating CYB003, its proprietary deuterated psilocybin analogue, for the treatment of major depressive disorder.

How psychedelic drugs might treat depression

Psychedelics feature in the BBC yet again. This time, Clare Tweedy dissects how psychedelics can help to treat depression.

Let doctors use MDMA to treat veterans with PTSD and depression, former ADF boss says

The former chief of the Australian defence force, Chris Barrie, is campaigning to remove barriers stymying doctors from using MDMA to treat veterans suffering post-traumatic stress disorder and depression, saying he hopes “common sense is going to prevail”.

Tripp Raises Another $11 Million; Unity CEO’s Metaverse Messaging

Tripp has raised $11.2 million in funding to help it continue to create meditation apps that power the “mindful metaverse.”

Cybin Announces Roster of 28 Expert Faculty and Advisors for its EMBARK Psychedelic Facilitator Training Program

Cybin has announced the team of 28 esteemed faculty and advisors who will lead the Company’s EMBARK Psychedelic Facilitator Training Program. Recognizing the crucial importance of supporting psychedelic study facilitators with quality training, Cybin has brought together recognized leaders and senior psychedelic-assisted psychotherapy trainers from leading universities and psychedelic research and training organizations.

Awakn Life Sciences Initiates Follow-on Behavioral Study to Focus on Gambling Disorder

Awakn Life Sciences has announced that they have initiated a larger behavioral addiction study investigating ketamine as a treatment for Gambling Disorder. The larger study announced today will include 42 patients who are suffering from Gambling Disorder and will see participants undergo a memory reactivation procedure, which is designed to weaken the link between reward and …

Ehave Inc. Announces Psychedelics Precision Medicine Platform For Clinical Research

Ehave Inc. has announced that its KetaDASH subsidiary will begin using precision medicine to improve patient outcomes through its partnership with Entheon Biomedical Corp.’s wholly-owned subsidiary, HaluGen Life Sciences. KetaDASH will become one of the first psychedelic companies to use precision medicine to test patients by using HaluGen’s expanded psychedelics genetic testing panel, which analyzes …

Lennham Pharmaceuticals Announces Issuance of U.S. Patent Covering Methods of Administering Psilocybin and Psilocin

Lennham Pharmaceuticals has announced that the United States Patent & Trademark Office issued U.S. Patent No. 11,344,564 with an expiration date of December 2041. This patent covers methods of treating neurological or psychiatric disorders in patients having reduced monoamine oxidase A (MAO-A) activity by administering a below-normal dose of psilocybin or psilocin.